# Makers Labs (NSE: MAKERSL) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/MAKERSL · Pivot · prices to 22 Oct 2026

Makers Labs (NSE: MAKERSL) closed at ₹191.02 on 22 Oct 2026, down 3.53% on the day. With a market capitalisation of ₹113 Cr, it ranks 2594th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 48× trailing earnings, against a return on equity of 3.2% in FY26. Its 52-week range is ₹150.00 (19 Aug 2026) to ₹236.00 (25 Aug 2026); the last close is 19.1% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹36 Cr (+5.5% year on year) and net profit ₹4 Cr (+125.3%), on a consolidated basis. Promoters held 61.27% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹191.02 |
| Market cap | ₹113 Cr |
| P/E (trailing) | 48 |
| ROE | 3.2% (FY26) |
| ROCE | 9.0% (FY26) |
| Debt to equity | 0.07 |
| 52-week high | ₹236.00 (25 Aug 2026) |
| 52-week low | ₹150.00 (19 Aug 2026) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹36 Cr | +5.5% | ₹4 Cr | +125.3% | ₹1.85 |
| Q3 FY26 | ₹36 Cr | +28.8% | ₹2 Cr | +740.7% | ₹1.59 |
| Q2 FY26 | ₹34 Cr | +15.6% | ₹1 Cr | −92.3% | −₹0.20 |
| Q1 FY26 | ₹35 Cr | +18.3% | ₹1 Cr | — | ₹0.74 |
| Q4 FY25 | ₹34 Cr | +21.9% | ₹2 Cr | — | ₹0.08 |
| Q3 FY25 | ₹28 Cr | +4.5% | ₹0 Cr | — | ₹0.50 |
| Q2 FY25 | ₹30 Cr | +18.0% | ₹10 Cr | — | ₹14.94 |
| Q1 FY25 | ₹30 Cr | +18.3% | −₹1 Cr | — | −₹1.67 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹121 Cr | ₹11 Cr |
| FY24 | ₹104 Cr | −₹5 Cr |
| FY23 | ₹101 Cr | −₹2 Cr |
| FY22 | ₹127 Cr | ₹12 Cr |
| FY21 | ₹69 Cr | ₹1 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 61.27%
- Domestic institutions: 0.39%
- Non-institutions: 38.34%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Krebs Biochemicals and Industries](https://app.pivotnow.in/stock/KREBSBIO) | ₹56.59 | ₹122 Cr | — | — |
| [Godavari Drugs](https://app.pivotnow.in/stock/GODAVARI) | — | ₹120 Cr | — | — |
| [Parnax Lab](https://app.pivotnow.in/stock/PARNAXLAB) | ₹104.00 | ₹119 Cr | 10.1 | — |
| [Pharmaids Pharm](https://app.pivotnow.in/stock/PHARMAID) | — | ₹113 Cr | — | — |
| [BALAXI PHARMACEUTICALS](https://app.pivotnow.in/stock/BALAXI) | ₹20.31 | ₹112 Cr | 78.1 | — |
| [Alpa Laboratories](https://app.pivotnow.in/stock/ALPA) | ₹51.70 | ₹109 Cr | 7.3 | — |

## Questions and answers

### What is the share price of Makers Labs today?

Makers Labs (NSE: MAKERSL) last closed at ₹191.02 on 22 Oct 2026. Its 52-week high is ₹236.00 and its 52-week low is ₹150.00.

### What is the market cap of Makers Labs?

Makers Labs' market capitalisation is ₹113 Cr (₹113 Cr) at the 22 Oct 2026 close, ranking 2594th among the NSE companies Pivot tracks.

### What is the P/E ratio of Makers Labs?

Makers Labs trades at a trailing P/E of 48. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 10.1.

### What is the ROE and ROCE of Makers Labs?

Return on equity was 3.2% in FY26 and return on capital employed was 9.0% in FY26 (consolidated figures).

### Is Makers Labs a debt-free company?

No. Makers Labs' debt-to-equity ratio was 0.07 in FY26, with total debt of ₹1 Cr.

### What were Makers Labs' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Makers Labs reported revenue of ₹36 Cr, +5.5% year on year, and net profit of ₹4 Cr, +125.3% year on year.

### What is the shareholding pattern of Makers Labs?

As of 30 Jun 2026: promoters 61.27%, domestic institutions 0.39%, non-institutions 38.34%.

### Who are Makers Labs' competitors?

The listed Pharma & Healthcare companies closest to Makers Labs by market cap are Krebs Biochemicals and Industries, Godavari Drugs, Parnax Lab, Pharmaids Pharm, BALAXI PHARMACEUTICALS and Alpa Laboratories.

### Is Makers Labs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Makers Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MAKERSL against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.